FDA approves Nucala for chronic obstructive pulmonary disease

The U.S. Food and Drug Administration has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup